AskBio Deal History & Licensing Activity
AskBio is a life sciences. Over the past three years, AskBio has been involved in 2 licensing and acquisition transactions, with a primary focus on Gene Therapy (4 deals). The company currently has 11 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
1
Active Trials
11
Top Modality
Gene Therapy
Focus Area
CNS Disorders
AskBio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AskBio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AB-1009 | Genethon | Gene Therapy | Unknown | license | Apr 2026 |
| AB-1009 | Genethon | Gene Therapy | Unknown | license | Apr 2026 |
AskBio Pipeline Focus
Therapeutic areas and modalities where AskBio is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
AskBio Strategic Signals
Key indicators of AskBio's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
AskBio Clinical Pipeline
AskBio has 11 active clinical trials across 3 development phases.
2
Unknown
6
Phase 1
3
Phase 2
See How Your Asset Matches AskBio's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About AskBio Licensing & Deal Activity
AskBio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, AskBio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AskBio include CNS Disorders (6 deals and trials), Rare Disease (4 deals and trials), Rare Disease (2 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, AskBio has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AskBio and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against AskBio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.